Related Experiment Video

Updated: Jun 17, 2026

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Ixabepilone, a new treatment option for metastatic breast cancer

Deborah L Toppmeyer1, Susan Goodin

  • 1Department of Medicine, Cancer Institute of New Jersey, New Brunswick, 08901 USA. toppmede@umdnj.edu

American Journal of Clinical Oncology
|December 22, 2009
PubMed

Insights

Ixabepilone offers a new treatment for metastatic breast cancer (MBC) resistant to standard therapies. This novel agent overcomes drug resistance, showing efficacy in patients with advanced MBC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic breast cancer (MBC) patients resistant to anthracyclines and taxanes face limited treatment options.
  • Tumor resistance to conventional chemotherapy necessitates novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of ixabepilone in patients with pretreated or resistant MBC.
  • To determine if ixabepilone can overcome common mechanisms of chemotherapeutic resistance.

Main Methods:

  • Ixabepilone, an epothilone B analog, targets β-tubulin and stabilizes microtubules, inducing apoptosis.
  • Clinical trials (Phase II and III) assessed ixabepilone as monotherapy and in combination with capecitabine.

Main Results:

  • Ixabepilone demonstrated clinical activity and a manageable safety profile in MBC.
  • Ixabepilone showed efficacy in patients resistant to anthracyclines, taxanes, and capecitabine.

Conclusions:

  • Ixabepilone is the first epothilone approved for MBC resistant to anthracyclines, taxanes, and/or capecitabine.
  • Ixabepilone represents a valuable therapeutic option for drug-resistant metastatic breast cancer.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...